← boardnext 2026-08next 2027-01
KURA
Kura Oncology, Inc.distress 5/10 · elevated risk$10.33-2%today-15% from 52w high
Oncology 1
Lead: Acute Myeloid Leukemia · target Menin · est. market ~$15B (approx, global)
Revenue
$18M
Liquidity
$39M
Runway
0.5 yrs
Shares 1y
+2%
Price & events
+13.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
-5.1%
1W
-0.5%
1M
+11.4%
3M
+19.7%
6M
+60.4%
1Y
-51.0%
2Y
-45.1%
5Y
-69.6%
All
Overview
- Market Cap
- $917.04M
- Enterprise Value
- $887.71M
- Volume
- 89.80K
- 52 Week Range
- $5.54 – $12.14
- Total Shares
- 88.77M
- Float Shares
- 70.42M
- Short %
- 17.45%
- % Held by Insiders
- 1.43%
- % Held by Institutions
- 96.84%
- RVOL
- 0.06x
- Beta
- 0.35
Pipeline stages · 3 programs
Ziftomenib, Venetoclax, Azacitidine (AZA)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Darlifarnib, Cabozantinib, Adagrasib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Tipifarnib, Alpelisib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-08-31 | Phase 1 | Ziftomenib, Fludarabine, Idarubicinbreakthroughpriority reviewfast trackorphan | AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type | 171 | recruiting |
| 2027-01 Estimated 50% readout ~2027-01-31 | Phase 1 | Darlifarnib, Cabozantinib, Adagrasib | Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer), Non Clear Cell Renal Cell Carcinoma (nccRCC) | — | recruiting |
| 2027-12 Estimated 50% readout ~2027-12-31 | Phase 1 | ziftomenib, imatinib mesylatebreakthroughpriority reviewfast trackorphan | Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors | — | recruiting |
| 2028-10-16 Estimated 50% readout ~2028-11-30 | Phase 1/2 | Ziftomenib, Midazolam, Itraconazolebreakthroughpriority reviewfast trackorphan | Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia | — | active not recruiting |
| 2030-04 Estimated 50% readout ~2030-05-01 | Phase 1 | Ziftomenib, Venetoclax, Azacitidinebreakthroughpriority reviewfast trackorphan | Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia | — | recruiting |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2031-11 Estimated 50% readout ~2032-01-15 | Phase 3 | Ziftomenib, Venetoclax, Azacitidine (AZA)breakthroughpriority reviewfast trackorphan | Acute Myeloid Leukemia (AML) | — | recruiting |
| 2025-08-29 | Phase 1/2 | Tipifarnib, Alpelisib | HNSCC | 45 | completed |
Catalyst news & presentations · 10
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- second half of 2025conferencedata presentationsecondaryPhase 1ziftomenib · KOMET-007 Phase 1b data of ziftomenib in combination with venetoclax/azacitidineSEC 8-K
- second half of 2025conferencedata presentationsecondaryPhase 1KO-2806 · FIT-001 Phase 1 data of KO-2806 in combination with cabozantinibSEC 8-K
- second half of 2025trial initiationsecondaryPhase 3ziftomenib · Start KOMET-017 intensive and non-intensive chemo Phase 3 studiesSEC 8-K
- second half of 2025conferencedata presentationsecondaryPhase 1tipifarnib · KURRENT-HN Phase 1 data of tipifarnib in combination with alpelisibSEC 8-K
- November 30, 2025PDUFAPDUFAziftomenib · Prescription Drug User Fee Act target action date for full approvalSEC 8-K
- 2025-10-24partnershipziftomenib · $30 million milestone payment received from Kyowa KirinSEC 8-K
- second quarter of 2025readoutPhase 2ziftomenib · Topline data from KOMET-001 to be presented at medical conferenceSEC 8-K
- second quarter of 2025regulatory submissionFiled (NDA/BLA)ziftomenib · NDA submission to FDASEC 8-K
- 2025-02-05fda agreementziftomenib · Successful End-of-Phase 1 meetings with FDA, agreeing on Phase 3 trial designs for frontline AMLSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $31 (+202% upside) · 12 analysts
- 2026-06-15CitizensMarket Outperform
- 2026-04-14Lake StreetBuy
- 2026-03-24MizuhoOutperform
- 2026-03-13UBSBuy
- 2026-03-06WedbushOutperform
- 2026-01-13HC Wainwright & Co.Buy
Recent news
- 2026-07-22(KURA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
- 2026-07-20Is Kura Oncology (KURA) Undervalued On New FIT 001 Trial Data? - Yahoo Finance
- 2026-07-14Kura Oncology to Present First Long-Term Follow-Up Data - GlobeNewswire
- 2026-07-14Long-term kidney cancer data from Kura's drug due July 24 - Stock Titan
- 2026-07-13Price to earnings forward of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
- 2026-07-08Kura Oncology: A Menin Inhibitor Launch With More Than One Way To Win (NASDAQ:KURA) - Seeking Alpha
- 2026-07-08Kura Oncology (KURA) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
- 2026-07-08Kura Oncology (KURA) Q4 2024 earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.